Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A Tupaia paramyxovirus vector system for targeting and transgene expression.

Engeland CE, Bossow S, Hudacek AW, Hoyler B, Förster J, Veinalde R, Jäger D, Cattaneo R, Ungerechts G, Springfeld C.

J Gen Virol. 2017 Sep;98(9):2248-2257. doi: 10.1099/jgv.0.000887. Epub 2017 Sep 8.

PMID:
28809150
2.

Ifit2 Is a Restriction Factor in Rabies Virus Pathogenicity.

Davis BM, Fensterl V, Lawrence TM, Hudacek AW, Sen GC, Schnell MJ.

J Virol. 2017 Aug 10;91(17). pii: e00889-17. doi: 10.1128/JVI.00889-17. Print 2017 Sep 1.

3.

Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V.

J Virol. 2017 Mar 29;91(8). pii: e02077-16. doi: 10.1128/JVI.02077-16. Print 2017 Apr 15.

4.

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24. doi: 10.1093/infdis/jiv251. Epub 2015 Jun 10.

5.

Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Hudacek AW, Al-Saleem FH, Willet M, Eisemann T, Mattis JA, Simpson LL, Schnell MJ.

Mol Ther Methods Clin Dev. 2014 Oct 1;1:14046. doi: 10.1038/mtm.2014.46. eCollection 2014.

6.

Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells.

Lawrence TM, Hudacek AW, de Zoete MR, Flavell RA, Schnell MJ.

J Virol. 2013 May;87(10):5848-57. doi: 10.1128/JVI.00203-13. Epub 2013 Mar 13.

7.

Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.

Hudacek AW, Navaratnarajah CK, Cattaneo R.

Cancer Gene Ther. 2013 Feb;20(2):109-16. doi: 10.1038/cgt.2012.92. Epub 2013 Jan 11.

8.

Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.

Miest TS, Yaiw KC, Frenzke M, Lampe J, Hudacek AW, Springfeld C, von Messling V, Ungerechts G, Cattaneo R.

Mol Ther. 2011 Oct;19(10):1813-20. doi: 10.1038/mt.2011.92. Epub 2011 May 24.

9.

A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys.

Devaux P, Hudacek AW, Hodge G, Reyes-Del Valle J, McChesney MB, Cattaneo R.

J Virol. 2011 Jan;85(1):348-56. doi: 10.1128/JVI.00802-10. Epub 2010 Oct 27.

10.

Agrobacterium tumefaciens type IV secretion protein VirB3 is an inner membrane protein and requires VirB4, VirB7, and VirB8 for stabilization.

Mossey P, Hudacek A, Das A.

J Bacteriol. 2010 Jun;192(11):2830-8. doi: 10.1128/JB.01331-09. Epub 2010 Mar 26.

11.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

12.
13.

At least do no harm.

Hudacek AG.

J Bone Joint Surg Am. 1989 Apr;71(4):479-80. No abstract available.

PMID:
2703506
14.

Experimental production of pigmented villonodular synovitis in dogs.

YOUNG JM, HUDACEK AG.

Am J Pathol. 1954 Jul-Aug;30(4):799-811. No abstract available.

Supplemental Content

Loading ...
Support Center